{
  "meta": {
    "title": "Guidelines_And_Protocols_Mini_Test",
    "url": "https://brainandscalpel.vercel.app/guidelines-and-protocols-mini-test-8ddafbfb.html",
    "scrapedAt": "2025-11-30T12:46:56.077Z"
  },
  "questions": [
    {
      "text": "1. Which of the following infants would not be considered high risk as per the NACO guidelines?",
      "choices": [
        {
          "id": 1,
          "text": "An infant born to HIV-positive mother who is not on ART"
        },
        {
          "id": 2,
          "text": "An infant born to a mother with maternal viral load not done after 32 weeks of pregnancy"
        },
        {
          "id": 3,
          "text": "An infant born to a mother with maternal viral load not suppressed after 32 weeks of pregnancy"
        },
        {
          "id": 4,
          "text": "An infant born to a mother who is newly identified as HIV-positive 11 weeks after delivery"
        }
      ],
      "correct_choice_id": 4,
      "solution": "An infant born to a mother who is newly identified as HIV-positive within 6 weeks of delivery should be considered as high risk, as per the NACO guidelines.<br><br> High-risk infants include:<br><br>* Infants born to HIV-positive mothers who are not on ART<br><br>* Maternal viral load is not done after 32 weeks of pregnancy<br><br>* Maternal viral load is not suppressed after 32 weeks of pregnancy<br><br>* Mother is newly identified as HIV-positive within 6 weeks of delivery<br><br>Low-risk infants are infants born to mothers with suppressed viral load (<1000 copies/mL) done any time after 32 weeks of pregnancy up to delivery<br><br>According to the National AIDS Control Organization (NACO), antiretroviral therapy (ART) should be given to all pregnant women, including during labor hours and breastfeeding. They are started on a triple-drug ART. ART should be given irrespective of the CD4 count and clinical stage, and treatment should be continued lifelong.<br><br>Immediate care of HIV-exposed infants includes wiping of the baby's mouth and nostrils, handling of infants with gloves, delayed cord clamping, and initiation of feeding. An infant born to an HIV-positive mother should be breastfed exclusively or by replacement feeds exclusively for 6 months.<br><br>Infants should receive ARV prophylaxis. A single drug or dual drug regimen is followed depending on the risk of transmission, which can be low or high risk.<br><br>* Low-risk infants are those born to mothers with a low viral load which is detected after 32 weeks of pregnancy till delivery. <br><br>* High-risk infants are those born to HIV-positive mothers, not on ART, with viral load not estimated beyond 32 weeks, viral load not suppressed after 32 weeks, or diagnosed with HIV within 6 weeks of delivery.<br><br><table>\n<tbody>\n<tr>\n<td><span class=\"WtpJAgSo\">HIV</span> <span class=\"fSVggSbE\">Risk</span> </td>\n<td><span class=\"VBwCrJsw\">ARV</span> <span class=\"dJOVGohg\">pr</span><span class=\"mIvlDhRv\">oph</span><span class=\"DBUwjJrT\">yla</span><span class=\"smRIBWBl\">xis</span></td>\n<td><span class=\"uERtzJbK\">Dura</span><span class=\"YzkXpqSG\">tion</span></td>\n</tr>\n<tr>\n<td><span class=\"btxYxhnj\">Low-</span><span class=\"DHohyrMy\">ri</span><span class=\"wyvnEBbw\">sk</span> <span class=\"QKDwblXM\">infa</span><span class=\"pahJWRqu\">nts</span></td>\n<td><strong><span class=\"btxYxhnj\">Syru</span><span class=\"HYaJueTH\">p</span> <span class=\"TktgBIiB\">nev</span><span class=\"enRuyYeg\">ir</span><span class=\"QDpkPzkD\">api</span><span class=\"UkRKRDCs\">ne</span> </strong><span class=\"kswEgugK\">or</span><strong> <span class=\"smRIBWBl\">Syr</span><span class=\"tFhVGINj\">up</span> <span class=\"KKwdhmXB\">zid</span><span class=\"hOWEnQNb\">ovud</span><span class=\"hlAtxycC\">ine</span> </strong><span class=\"pahJWRqu\">(in</span> <span class=\"EUVshISH\">sit</span><span class=\"aRJaWlNp\">ua</span><span class=\"vdPDXcBz\">tion</span><span class=\"YUxNIZHu\">s</span> <span class=\"OqdGquXP\">whe</span><span class=\"RpIIWXQS\">re</span> <span class=\"XjoerOam\">Nevi</span><span class=\"UPscEWFz\">ra</span><span class=\"SwYuLnft\">pine</span> <span class=\"WtpJAgSo\">wil</span><span class=\"OqdGquXP\">l</span> <span class=\"mbiypDcV\">not</span> <span class=\"EQqgZoPg\">be</span> <span class=\"AwWCzBeE\">effe</span><span class=\"AcIidyOy\">ct</span><span class=\"EFfQUsRW\">ive,</span> <span class=\"dXwUCDZE\">as</span> <span class=\"aRJaWlNp\">men</span><span class=\"wPicjEDH\">tio</span><span class=\"IqGWzgOp\">ned</span> <span class=\"pXlLyoTj\">belo</span><span class=\"mbiypDcV\">w)</span><br/><br/></td>\n<td><span class=\"oAefMaQs\">Bi</span><span class=\"UPscEWFz\">rth</span> <span class=\"dXwUCDZE\">to</span> <strong><span class=\"IqGWzgOp\">6</span> <span class=\"qUZPIcjK\">week</span><span class=\"mbvGhJID\">s</span></strong> <span class=\"QKDwblXM\">of</span> <span class=\"zirIsyPe\">ag</span><span class=\"VTfVzKVU\">e,</span> <span class=\"GlGNJvrV\">ir</span><span class=\"EUVshISH\">re</span><span class=\"EUVshISH\">sp</span><span class=\"nnAssSPA\">ec</span><span class=\"JuBwzcRb\">tive</span> <span class=\"DHohyrMy\">of</span> <span class=\"enRuyYeg\">fe</span><span class=\"dXwUCDZE\">edin</span><span class=\"stDDHwUb\">g</span> </td>\n</tr>\n<tr>\n<td><span class=\"QDpkPzkD\">High</span><span class=\"XMHPLPAW\">-ri</span><span class=\"qUZPIcjK\">sk</span> <span class=\"oAefMaQs\">infa</span><span class=\"YUxNIZHu\">nt</span><span class=\"SwYuLnft\">s</span></td>\n<td><strong><span class=\"DHohyrMy\">Syru</span><span class=\"ZSbOLKAR\">p</span> <span class=\"mbvGhJID\">nev</span><span class=\"HYaJueTH\">irap</span><span class=\"gbGxGVpg\">ine</span> <span class=\"UEFKSlGs\">+</span> <span class=\"pXlLyoTj\">sy</span><span class=\"ECNiVvub\">rup</span> <span class=\"uqkrJKDM\">zido</span><span class=\"hOWEnQNb\">vudi</span><span class=\"VYhwzoNM\">ne</span></strong></td>\n<td>\n<p><span class=\"wyvnEBbw\">If</span> <span class=\"IqGWzgOp\">excl</span><span class=\"bOdUeviA\">usiv</span><span class=\"IqGWzgOp\">e</span> <span class=\"gbGxGVpg\">re</span><span class=\"QKDwblXM\">pl</span><span class=\"OQiJhzdU\">ace</span><span class=\"fSVggSbE\">men</span><span class=\"azMnXaKB\">t</span> <span class=\"uERtzJbK\">fe</span><span class=\"dXwUCDZE\">edin</span><span class=\"OQiJhzdU\">g:</span> <span class=\"ZSbOLKAR\">Bi</span><span class=\"bHKNoRZh\">rth</span> <span class=\"hlAtxycC\">to</span><strong> <span class=\"pahJWRqu\">6</span> <span class=\"mbvGhJID\">we</span><span class=\"sQIICMtD\">ek</span><span class=\"btxYxhnj\">s</span></strong></p>\n<p><span class=\"wyvnEBbw\">If</span> <span class=\"YUxNIZHu\">excl</span><span class=\"HYaJueTH\">us</span><span class=\"kswEgugK\">ive</span> <span class=\"pXlLyoTj\">brea</span><span class=\"uqkrJKDM\">st</span><span class=\"wAINmZWI\">feed</span><span class=\"pahJWRqu\">ing:</span> <span class=\"vdPDXcBz\">Birt</span><span class=\"qMNTIROE\">h</span> <span class=\"FhsuqBHA\">ti</span><span class=\"ddqEFkfj\">ll</span> <strong><span class=\"dJOVGohg\">12</span> <span class=\"cpcAnhll\">week</span><span class=\"wyvnEBbw\">s</span></strong> </p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Add syp. Zidovudine in situations where Nevirapine will not be effective :<br><br>* An infant born to a mother with confirmed HIV-2 or HIV-1 and HIV-2 combined infections<br><br>* An infant born to a mother who had received a single dose of Nevirapine during an earlier pregnancy or delivery<br><br>* An infant born to a mother who is on a PI-based ART regimen due to treatment failure<br><br>When Zidovudine syrup is not available, syrup Lopinavir/ritonavir should be used after 14 days of birth.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "2. Which of the following is an indication for a computed tomography (CT) scan in an adult patient with a head injury within 1 hour of presentation, as per the NICE guidelines?<br><br>NICE: National Institute for Health and Care Excellence<br><br>* Glasgow Coma Score (GCS) <13 at any point<br><br>* Coagulopathy (e.g., aspirin, warfarin, or rivaroxaban use)<br><br>* Focal neurological deficit<br><br>* Suspected basal skull fracture<br><br>* Retrograde amnesia >30 minutes",
      "choices": [
        {
          "id": 1,
          "text": "1, 3 and 4"
        },
        {
          "id": 2,
          "text": "2 and 5"
        },
        {
          "id": 3,
          "text": "1, 2 and 4"
        },
        {
          "id": 4,
          "text": "3 and 4"
        }
      ],
      "correct_choice_id": 1,
      "solution": "According to the National Institute for Health and Care Excellence (NICE) Guidelines for Computed Tomography (CT) in Head Injury:<br><br>Indications for CT imaging within 1 hour of the following risk factors being identified:<br><br>* Glasgow Coma Score (GCS) <13 at any point<br><br>* Glasgow Coma Scale (GCS) score of less than 15 two hours post-injury<br><br>* Presence of focal neurological deficits<br><br>* Suspected open, depressed, or basal cranial fracture<br><br>* multiple episodes of vomiting.<br><br>* Post-traumatic seizure<br><br>Indications for CT imaging within 8 hours:<br><br>* Age >65 years<br><br>* Coagulopathy (e.g., aspirin, warfarin, or rivaroxaban use)<br><br>* Dangerous mechanism of injury (e.g., fall from a height, road traffic accident)<br><br>* Retrograde amnesia >30 minutes<br><br>Pearl PM0195: NICE Guidelines for CT in Head Injury<br><br>National Institute for Health and Care Excellence (NICE) Guidelines for Computed Tomography (CT) in Head Injury<br><br>Indications for CT imaging within 1 hour of the following risk factors being identified:<br><br>* Glasgow Coma Score (GCS) ≤ 12 on initial assessment<br><br>* GCS <15 at 2 hours after injury on assessment in an emergency department<br><br>* Focal neurological deficit<br><br>* Suspected open, depressed, or basal skull fracture<br><br>* More than one episode of vomiting<br><br>* Post-traumatic seizure<br><br>Indications for CT imaging within 8 hours:<br><br>* Age >65 years<br><br>* Bleeding or clotting disorders<br><br>* Dangerous mechanism of injury (e.g., fall from a height of >1 meter/5 stairs, road traffic accident)<br><br>* Retrograde amnesia >30 minutes",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "3. An 11-month-old child is brought to the emergency room with a history of 12-14 episodes of loose, watery, non-blood-stained stools for the last two days. On examination, the temperature is 98.8 F, pulse rate is 130/minute, and respiratory rate is 45/minute. The child appears lethargic with sunken eyes and skin turgor is reduced with recoil in 3 secs. Which of the following is incorrect about the management protocol in this patient as per the WHO IMNCI plans?",
      "choices": [
        {
          "id": 1,
          "text": "The fluid replacement should be done over 6 hours"
        },
        {
          "id": 2,
          "text": "Both Ringer's lactate and normal saline can be used for resuscitation"
        },
        {
          "id": 3,
          "text": "The total fluid requirement in this patient is 75 mL/kg"
        },
        {
          "id": 4,
          "text": "ORS can be given as a bridge to definitive management"
        }
      ],
      "correct_choice_id": 3,
      "solution": "This child with a history of watery diarrhea has severe dehydration based on examination findings (sunken eyes, tachycardia, lethargy). This child should be started on IV fluids (either Ringer's Lactate or Normal saline) at the rate of 100 mL/kg over 6 hours as she is less than 12 months of age. <br><br>WHO IMNCI PLANS:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f174f3e0e9654f8898e1d3176b16b078x510x428.JPEG\" alt=\"Explanation Image\"><br><br>Pearl PM1882: Symptoms associated with different levels of dehydration<br><br><table>\n<tbody>\n<tr>\n<td><span><strong>Symptoms</strong></span></td>\n<td><span><strong>No or minimal dehydration</strong></span></td>\n<td><span><strong>Mild to moderate dehydration</strong></span></td>\n<td><span><strong>Severe dehydration</strong></span></td>\n</tr>\n<tr>\n<td><span><strong>Loss of body weight</strong></span></td>\n<td><span>&lt;3%</span></td>\n<td><span>3–9%</span></td>\n<td><span>&gt;9%</span></td>\n</tr>\n<tr>\n<td><span><strong>Mental status</strong></span></td>\n<td><span>Well; <strong>alert</strong></span></td>\n<td><span>Fatigued or <strong>irritable</strong></span></td>\n<td><span><strong>Lethargic </strong>or unconscious</span></td>\n</tr>\n<tr>\n<td><span><strong>Thirst</strong></span></td>\n<td><span>Drinks normally</span></td>\n<td><span><strong>Thirsty</strong>; eager to drink</span></td>\n<td><span>Drinks poorly</span></td>\n</tr>\n<tr>\n<td><span><strong>Heart rate</strong></span></td>\n<td><span>Normal</span></td>\n<td><span>Normal to increased</span></td>\n<td><span>Tachycardia</span></td>\n</tr>\n<tr>\n<td><span><strong>Quality of pulse</strong></span></td>\n<td><span>Normal</span></td>\n<td><span>Normal to decreased</span></td>\n<td><span>Weak, thready or impalpable</span></td>\n</tr>\n<tr>\n<td><span><strong>Skin turgor test</strong></span></td>\n<td><span>Instant recoil</span></td>\n<td><span><strong>Recoil in &lt;2</strong> <strong>sec</strong></span></td>\n<td><span>Recoil in &gt;2 sec</span></td>\n</tr>\n<tr>\n<td><span><strong>Capillary refill</strong></span></td>\n<td><span>Normal</span></td>\n<td><span>Prolonged</span></td>\n<td><span>Prolonged</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM1883: Treatment of dehydration based on severity<br><br>Plan A: For no dehydration or minimal dehydration. ORS is administered after each loose stool.<br><br><table>\n<tbody>\n<tr>\n<td><strong>Age</strong></td>\n<td><strong>Amount </strong></td>\n</tr>\n<tr>\n<td>&lt;2 years</td>\n<td>50–100 mL</td>\n</tr>\n<tr>\n<td>2-10 years</td>\n<td>100–200 mL</td>\n</tr>\n<tr>\n<td>&gt;10 years</td>\n<td>As much fluid as they want</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Plan B: For moderate dehydration.<br><br>The amount of oral rehydration solution (ORS) to be given is 75 mL/kg body weight (wt × 75).<br><br>Plan C: Severe dehydration<br><br><table>\n<tbody>\n<tr>\n<td><strong>Age</strong></td>\n<td>First, give<strong> 30 mL/kg in</strong></td>\n<td>Followed by <strong>70 mL/kg in</strong></td>\n<td>Total<strong> 100 mL/kg in</strong></td>\n</tr>\n<tr>\n<td>Infants (under 12 months)</td>\n<td>1 hr</td>\n<td>5 hrs</td>\n<td> 6 hrs</td>\n</tr>\n<tr>\n<td>Older</td>\n<td>30 min</td>\n<td>2½ hrs</td>\n<td> 3 hrs</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Note: Ringer lactate (ideal) or normal saline is used as intravenous fluids.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "4. An 18-month-old baby was brought with complaints of fever and fast breathing. According to IMNCI, what should be the respiratory rate to diagnose this baby with pneumonia?<br><br>IMNCI: Integrated management of neonatal and childhood illness",
      "choices": [
        {
          "id": 1,
          "text": ">/=40"
        },
        {
          "id": 2,
          "text": ">/=60"
        },
        {
          "id": 3,
          "text": ">/=30"
        },
        {
          "id": 4,
          "text": ">/=50"
        }
      ],
      "correct_choice_id": 1,
      "solution": "An 18-month-old baby presenting with fever and fast breathing should have a respiratory rate of >40 to be diagnosed with pneumonia according to IMNCI.<br><br>According to the IMNCI, three key clinical signs are used to assess a sick child with suspected pneumonia:<br><br>* Respiratory rate (RR): distinguishes children who have pneumonia from those who do not. Children are classified under pneumonia if:<br><br>* > 60 breaths per minute if age  is < 2 months <br><br>* > 50/min RR for infants 2 months to 12 months<br><br>* > 40/min RR for children 12 months to 5 years of age<br><br>* Lower chest wall indrawing refers to the indrawing of the lower chest wall with respect to the child's breathing and indicates pneumonia<br><br>* Stridor indicates those with severe pneumonia requiring hospital admission.<br><br>The revised classification of acute respiratory infections is simplified to include only two categories of pneumonia:<br><br>* Cough and cold, no pneumonia - requires home remedy<br><br>* Pneumonia - with fast breathing and/or chest indrawing, which requires home therapy with oral amoxicillin.<br><br>* Severe pneumonia - pneumonia with any general danger sign, which requires a referral and injectable therapy. <br><br>Danger signs of severe pneumonia are: <br><br>* Not able to drink<br><br>* Persistent vomiting<br><br>* Convulsions<br><br>* Lethargic or unconscious<br><br>* Stridor in a calm child<br><br>* Severe malnutrition<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/402ec23059f642f1840119590a5d55fdx1280x711.PNG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "5. According to the malaria treatment guidelines, which of the following statements is true?",
      "choices": [
        {
          "id": 1,
          "text": "Primaquine is contraindicated in infants and pregnant women"
        },
        {
          "id": 2,
          "text": "Presumptive treatment with chloroquine should be given"
        },
        {
          "id": 3,
          "text": "Primaquine is to be given for 7 days in falciparum malaria"
        },
        {
          "id": 4,
          "text": "ACT should not be given in falciparum malaria"
        }
      ],
      "correct_choice_id": 1,
      "solution": "According to guidelines, primaquine is contraindicated in infants and pregnant women.<br><br>To prevent relapse from Plasmodium vivax or Plasmodium ovale malaria in children and adults a 14-day course of primaquine is given in all transmission settings. It is not used in pregnant women, infants aged < 6 months, women breastfeeding infants aged < 6 months, and people with G6PD deficiency.<br><br>Artemisinin combination therapy (ACT) (Artesunate 3 days + sulphadoxine-pyrimethamine 1 day) should be given to all confirmed P. falciparum cases along with single dose of primaquine on Day 2.<br><br>According to the revised drug policy 2013, there is no scope of presumptive treatment in malaria control in India.<br><br>Pearl PM1696: Treatment of Malaria<br><br><table>\n<tbody>\n<tr>\n<td> </td>\n<td>\n<p><strong> Drug of Choice</strong></p>\n</td>\n<td>\n<p><strong> Primaquine Dose</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. vivax malaria </strong></p>\n</td>\n<td>\n<p><strong>Chloroquine </strong>25 mg/kg divided as:</p>\n<p>10mg/kg on day 1</p>\n<p>10mg/kg on day 2</p>\n<p>5mg/kg on day 3</p>\n</td>\n<td>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. falciparum malaria</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p> </p>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days </p>\n</td>\n<td>\n<p> </p>\n<p>0.75mg/kg on day 2</p>\n<p>0.75mg/kg on day 2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mixed infection</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days</p>\n</td>\n<td>\n<p> </p>\n<p>0.25 mg/kg for 14 days</p>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Resistance to ACT</strong></p>\n</td>\n<td>\n<p> </p>\n<p>Quinine</p>\n</td>\n<td>\n<p> </p>\n<p><strong> -</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Severe malaria</strong></p>\n</td>\n<td>\n<p>IV Artesunate</p>\n</td>\n<td>\n<p>-</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. vivax</strong></p>\n</td>\n<td>\n<p>Chloroquine</p>\n</td>\n<td>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. falciparum</strong></p>\n</td>\n<td>\n<p>1<sup>st </sup>trimester: <strong>Quinine</strong></p>\n<p>2<sup>nd</sup> and 3<sup>rd</sup> trimester<strong>: Area specific ACT</strong></p>\n</td>\n<td>\n<p> </p>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>ACT: artemisinin-based combination therapy<br><br>AL: artemether-lumefantrine<br><br>SP: Sulfadoxine-Pyrimethamine",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "6. A 47-year-old patient presents with 1 hypopigmented and anesthetic skin patch on his right upper limb, along with thickening of the right median and ulnar nerve. Which of the following treatment regimens should be prescribed to this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Rifampin 600 mg daily, Clofazimine 300 mg once/month and 50 mg daily, Dapsone 100 mg daily x 12 months"
        },
        {
          "id": 2,
          "text": "Rifampin 600 mg daily, Clofazimine 300 mg once/month and 50 mg daily, Dapsone 100 mg daily x 6 months"
        },
        {
          "id": 3,
          "text": "Rifampin 600 mg once/month, Clofazimine 300 mg once/month and 50 mg daily, Dapsone 100 mg daily x 6 months"
        },
        {
          "id": 4,
          "text": "Rifampin 600 mg once/month, Clofazimine 300 mg once/month and 50 mg daily, Dapsone 100 mg daily x 12 months"
        }
      ],
      "correct_choice_id": 4,
      "solution": "The given patient has 1 hypopigmented, anesthetic patch, but has the involvement of 2 nerves. Thus, he has multibacillary (MB) leprosy. The following drugs are given for a period of 12 months for the treatment of multibacillary leprosy:<br><br>* Rifampin 600 mg once/month<br><br>* Clofazimine 300 mg once/month and 50 mg daily<br><br>* Dapsone 100 mg daily<br><br>Management of leprosy is based on the bacterial load. WHO defines paucibacillary (PB) disease as the presence of no bacilli on smears or biopsy and less than or equal to 5 skin lesions with no peripheral nerve involved. MB leprosy is characterized by bacilli on smears or biopsies of more than 5 skin lesions and/or 1 or more peripheral nerve involvement.<br><br>The current recommendation by WHO is to treat PB leprosy with a combination of 3 drugs - rifampicin, dapsone, and clofazimine (maroon blister pack) for 6 months. Meanwhile, multibacillary (MB) leprosy is treated using the same 3 drugs for a duration of 12 months. While the NLEP guidelines earlier mentioned a 2-drug MDT for PB leprosy, the National Strategic Plan and Roadmap for Leprosy (2023-2027) now recommends a uniform MDT of 3 drugs for both PB and MB leprosy.<br><br>Chemoprophylaxis for leprosy should be given in:<br><br>* Contacts who are more than 2 years old<br><br>* Individuals who have maintained close and regular contact, amounting to at least 20 hours per week for over three months, with a patient diagnosed with leprosy<br><br>A single dose of rifampicin is recommended for the close contact of a patient with leprosy, provided they do not develop any signs or symptoms pertaining to leprosy.<br><br>Pearl PM1967: Characteristics of Ridley Jopling Classification in Leprosy<br><br><table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>TT (Tuberculoid Leprosy)</strong></td>\n<td><strong>BT (Borderline Tuberculoid)</strong></td>\n<td><strong>BB (Borderline)</strong></td>\n<td><strong>BL(Borderline Lepromatous)</strong></td>\n<td><strong>LL (Lepromatous Leprosy)</strong></td>\n</tr>\n<tr>\n<td><strong>Number and Type of lesions</strong></td>\n<td><strong>1-3</strong> <strong>well</strong><br/><strong>defined</strong> hypopigmented macule(s) or plaque(s) with elevated sloping borders '<strong>saucer right side up'</strong> lesion. Asymmetrical distribution.</td>\n<td>\n<p>Hypopigmented macules or plaques, variable in number, up to <strong>10</strong>.</p>\n<p>Occasionally showing fingerlike extensions<br/>(<strong>pseudopodia</strong>) or <strong>satellite lesions</strong></p>\n</td>\n<td>\n<p>Hypopigmented macules or plaques with annular, ‘<strong>swiss </strong><strong>cheese’</strong> /inverted saucer/punched out appearance</p>\n<p>Variable in number<br/><strong>(10–30)</strong></p>\n</td>\n<td>\n<p><strong>Numerous</strong> hypopigmented macules, papules, plaques, and some nodules, lesions with <strong>swiss </strong><strong>cheese’</strong> /inverted saucer/punched out appearance <strong>almost symmetrical</strong> in<br/>distribution</p>\n</td>\n<td>\n<p>Hypopigmented macules, plaques,<br/>and nodular lesions</p>\n<p><strong>Innumerable</strong> lesions<br/>showing <strong>perfect  symmetrical </strong>distribution</p>\n</td>\n</tr>\n<tr>\n<td><strong>Size of Lesion</strong></td>\n<td>Variable size,<strong>usually</strong><br/><strong>large</strong></td>\n<td>Variable size, some lesions are large</td>\n<td>Variable</td>\n<td>Variable, usually small</td>\n<td><strong>Small</strong></td>\n</tr>\n<tr>\n<td><strong>Surface of Lesion</strong></td>\n<td><strong>Dry, scaly and infiltrated</strong></td>\n<td>Dry, scaly infiltrated (but less than TT)</td>\n<td>Dry, scaly and slightly shiny</td>\n<td>Shiny (less than LL)</td>\n<td><strong>Shiny</strong></td>\n</tr>\n<tr>\n<td><strong>Sensations</strong></td>\n<td><strong>Absent. </strong></td>\n<td>Markedly diminished</td>\n<td>Moderately diminished</td>\n<td>Slightly diminished</td>\n<td><strong>May be normal</strong></td>\n</tr>\n<tr>\n<td><strong>Peripheral Nerves</strong></td>\n<td>\n<p><strong>Asymmetrical, single nerve</strong><br/>enlargement.</p>\n<p>Nerve to patch may<br/>be palpable</p>\n</td>\n<td>Asymmetrical enlargement of few nerves</td>\n<td>Asymmetrical involvement of several nerves</td>\n<td><strong>Increasingly symmetric</strong> enlargement of nerves</td>\n<td>\n<p><strong>Symmetrical</strong><br/><strong>involvement</strong> of<br/>nerve trunks with<br/>‘<strong>glove and stocking</strong><br/><strong>anesthesia’</strong>.</p>\n<p>Nerves may feel normal on<br/>palpation or may be<br/>thickened.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Hair</strong></td>\n<td><strong>Absent</strong></td>\n<td>Markedly diminished</td>\n<td>Moderately diminished</td>\n<td>Slightly diminished</td>\n<td><strong>Almost normal (initially)</strong></td>\n</tr>\n<tr>\n<td><strong>Bacteriology on Split Skin Smear</strong></td>\n<td><strong>Negative</strong></td>\n<td>Negative or Scanty Bacilli</td>\n<td>Moderate number of AFB present</td>\n<td>Large number of AFB </td>\n<td>Plenty of AFB including <strong>Globi</strong> are seen</td>\n</tr>\n<tr>\n<td><strong>Typical Lepra Reaction</strong></td>\n<td>Type 1</td>\n<td>Type 1</td>\n<td>Type 1/Type 2</td>\n<td>Type 1/Type 2</td>\n<td>Type 2</td>\n</tr>\n<tr>\n<td><strong>Lepromin Reactivity</strong></td>\n<td>\n<p><strong>Strongly Positive</strong></p>\n<p>(+++)</p>\n</td>\n<td>\n<p>Weakly Positive</p>\n<p>(+ or ++)</p>\n</td>\n<td>Negative/ Weakly positive</td>\n<td>Negative</td>\n<td><strong>Negative</strong></td>\n</tr>\n<tr>\n<td><strong>Histopathology</strong></td>\n<td>\n<p><strong>Dermal Tuberculoid granulomas</strong> (arranged around nerves)</p>\n<p><strong>No bacilli are seen</strong></p>\n</td>\n<td>\n<p>Fewer Tuberculoid granulomas</p>\n<p><strong>Grenz clear zone</strong> in upper papillary dermis <strong>starts to form</strong></p>\n<p>Nerves are<br/>replaced by granulomas</p>\n<p>Fragmented<br/>bacilli are seen with AFB stain</p>\n</td>\n<td>\n<p>Tuberculoid granulomas less prominent</p>\n<p>Grenz zone is more prominent</p>\n<p>Transverse section of the nerve shows <strong>cut onion appearance</strong></p>\n</td>\n<td>\n<p>Prominent foam cells</p>\n<p>Prominent Grenz zone</p>\n<p>Nerves show concentric perineural cell infiltration<br/>and <strong>more conspicuous cut onion appearance</strong>.</p>\n<p>AFB are plentiful, including<br/><strong>small globi</strong></p>\n</td>\n<td>\n<p><strong>Most prominent Grenz zone</strong></p>\n<p><strong>Expansive and loose granulomas</strong></p>\n<p>Plenty of macrophages<br/>loaded with AFB- <strong>Virchow cells or Lepra cells</strong></p>\n<p>AFB are seen in endothelial cells and Schwann cells as clumps - <strong>globi</strong></p>\n<p>Nerves are minimally<br/>involved.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM1966: Lepra Reactions<br><br>Lepra Reactions:<br><br><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type 1 Reaction</strong></p>\n<p>(Reversal/Upgrading)</p>\n</td>\n<td>\n<p><strong>Type 2 Reaction</strong></p>\n<p>(Erythema Nodosum Leprosum)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mainly seen in the <strong>Borderline</strong> spectrum (BT, BB, BL)</p>\n<p><strong>Most severe</strong> in Borderline Lepromatous(BL) leprosy</p>\n</td>\n<td>Mainly seen in <strong>LL</strong>(50%)&gt;BL(15%)</td>\n</tr>\n<tr>\n<td>\n<p>Usually seen <strong>within 12 months</strong> of initiation of Multidrug Therapy</p>\n</td>\n<td><strong>Unrelated</strong> to Multidrug therapy. May occur before, during or after treatment</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type 4</strong> Hypersensitivity</p>\n<p>Due to <strong>enhanced cell-mediated response</strong> increased destruction of bacilli following treatment in reversal</p>\n</td>\n<td>\n<p><strong>Type 3</strong> Hypersensitivity</p>\n<p>Primarily Humoral</p>\n<p>(<strong>Immune complex Deposition</strong> in tissues and vessels)</p>\n<p>Cytokine involved - <strong>TNF-α</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inflammation of <strong>existing skin lesions</strong> (red, painful edematous skin lesions) that may <strong>ulcerate</strong></p>\n<p>New lesions may occur (rare)</p>\n<p><strong>Neuritis</strong> and <strong>Nerve abscesses </strong>(red, painful inflamed nerves)</p>\n</td>\n<td>\n<p><strong>New, erythematous and tender</strong>, subcutaneous and dermal nodules that are widely distributed over extremities and face</p>\n<p>Existing lesions do not change</p>\n</td>\n</tr>\n<tr>\n<td><strong>No</strong> systemic involvement</td>\n<td><strong>Systemic symptoms</strong> present - fever, myalgias, arthralgias, anorexia, keratitis, iritis, nephritis, synovitis, orchitis, lymphadenopathy</td>\n</tr>\n<tr>\n<td>\n<p><strong>Treatment:</strong></p>\n<p>Supportive therapy for mild reactions with <strong>NSAIDs</strong></p>\n<p>In case of severe reactions with neuritis and eye lesions- <strong>Oral corticosteroids</strong></p>\n<p><strong>(Drug of Choice)</strong></p>\n<p>Nerve Abscess - Additional <strong>surgical drainage</strong></p>\n<p>Other drugs: Clofazimine, Cyclosporine</p>\n</td>\n<td>\n<p><strong>Treatment:</strong></p>\n<p><strong>Oral Corticosteroids - First-line drug<br/><br/>Clofazimine </strong>(Steroid dependent ENL)<strong><br/></strong></p>\n<p><strong>Thalidomide -most effective </strong>but not used first due to various side effects</p>\n<p> </p>\n<p> </p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM0341: WHO proposed Multi Drug Therapy (MDT) for the treatment of Leprosy<br><br>WHO proposed Multi-Drug Therapy (MDT) for the treatment of Leprosy<br><br><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Age group</strong></p>\n</td>\n<td>\n<p><strong>Drug</strong></p>\n</td>\n<td>\n<p><strong>Duration of Treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adult</p>\n</td>\n<td>\n<p><strong>Rifampicin 600 mg</strong> once a month</p>\n<p>+</p>\n<p><strong>Clofazimine 300 mg</strong> once a month and <strong>50 mg daily</strong></p>\n<p>+</p>\n<p><strong>Dapsone 100 mg</strong> daily</p>\n<p> </p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children (10–14 years)</p>\n</td>\n<td>\n<p>Rifampicin <strong>450 mg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>150 mg</strong> once a month and 50 mg <strong>alternate days</strong>.</p>\n<p>+</p>\n<p>Dapsone <strong>50 mg</strong> daily </p>\n<p>                             </p>\n</td>\n<td> \n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children &lt;10 years old or &lt;40 kg</p>\n</td>\n<td>\n<p>Rifampicin <strong>10 mg/kg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>100mg</strong> once a month, 50mg <strong>twice weekly</strong></p>\n<p>+</p>\n<p>Dapsone <strong>2 mg/kg</strong> daily</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n<p> </p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "7. Match the following declarations to their significance.<br><br><table>\n<tbody>\n<tr>\n<td><strong>Declarations</strong></td>\n<td><strong>Significant decisions taken:</strong></td>\n</tr>\n<tr>\n<td>\n<p>1. Declaration of Istanbul</p>\n</td>\n<td>\n<p>A. Hunger strikes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2. Declaration of Taipei</p>\n</td>\n<td>\n<p>B. Organ trafficking</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3. Declaration of Oslo</p>\n</td>\n<td>C. Torture</td>\n</tr>\n<tr>\n<td>\n<p>4. Declaration of Malta</p>\n</td>\n<td>\n<p>D. Ethical principles regarding human experimentation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5. Declaration of Helsinki</p>\n</td>\n<td>\n<p>E. Therapeutic abortions</p>\n</td>\n</tr>\n<tr>\n<td> </td>\n<td>F. Biobanks </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-A, 2-B, 3-C, 4-D, 5-E"
        },
        {
          "id": 2,
          "text": "1-B, 2-F, 3-E, 4-A, 5-D"
        },
        {
          "id": 3,
          "text": "1-F, 2-D, 3-B, 4-A, 5-E"
        },
        {
          "id": 4,
          "text": "1-B, 2-A, 3-D, 4-C, 5-E"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The correct option is 1-B, 2-F, 3-E, 4-A, 5-D.<br><br><table>\n<tbody>\n<tr>\n<td><span class=\"ujPUriZZ\">Decl</span><span class=\"PDRjDLcU\">ara</span><span class=\"slWdGrRE\">tion</span></td>\n<td><span class=\"KzGqZpju\">Si</span><span class=\"mhyqUmzI\">gnif</span><span class=\"NCJbqSkh\">ic</span><span class=\"gAQDtczp\">ance</span></td>\n</tr>\n<tr>\n<td><strong><span class=\"yuHUIfWq\">Ista</span><span class=\"OhEbinxR\">nb</span><span class=\"VmkSBuYK\">ul</span></strong></td>\n<td><span class=\"bSbsMkZY\">Ad</span><span class=\"ZeyUVeTO\">dr</span><span class=\"gAQDtczp\">esse</span><span class=\"yuHUIfWq\">s</span> <span class=\"GTrxQeFG\">prob</span><span class=\"YZItQZhB\">lem</span> <span class=\"VmkSBuYK\">stat</span><span class=\"dPkdwlES\">eme</span><span class=\"KbNXgHnh\">nt</span><span class=\"dXaQHAVY\">s</span> <span class=\"GTrxQeFG\">wi</span><span class=\"BbwPapQi\">th</span> <span class=\"pUJrallU\">rega</span><span class=\"mhyqUmzI\">rd</span><span class=\"OhEbinxR\">s</span> <span class=\"dPkdwlES\">to</span> <span class=\"OMFFBaFb\">the</span> <span class=\"pwuONisv\">sh</span><span class=\"NrHhzTxg\">orta</span><span class=\"UbpYdtek\">ge</span> <span class=\"FIiuoCzU\">of</span> <span class=\"lwaTBkLk\">glo</span><span class=\"ZeyUVeTO\">bal</span> <span class=\"afenwPlA\">or</span><span class=\"lnOALJQV\">gans</span> <span class=\"ZcoxpzJJ\">for</span> <span class=\"XPoKflXW\">tran</span><span class=\"umIyCNKJ\">spla</span><span class=\"dPkdwlES\">nts</span> <span class=\"epNqzPAR\">and</span> <strong><span class=\"bSbsMkZY\">orga</span><span class=\"FIiuoCzU\">n</span> <span class=\"XaOQRNsn\">traf</span><span class=\"VmkSBuYK\">fi</span><span class=\"SuVNBZbq\">ck</span><span class=\"Bkivskjj\">ing</span></strong></td>\n</tr>\n<tr>\n<td><strong><span class=\"ACKoyvEy\">Taip</span><span class=\"fDcUWsKx\">ei</span></strong></td>\n<td><span class=\"PXWaTciu\">Stat</span><span class=\"pUJrallU\">emen</span><span class=\"UROZKPEF\">ts</span> <span class=\"zRDqozzn\">on</span> <span class=\"cIAIpkTs\">ethi</span><span class=\"gAQBlnIx\">ca</span><span class=\"rlmifLSY\">l</span> <span class=\"YAkdratS\">co</span><span class=\"PXWaTciu\">nsid</span><span class=\"wEnFNlUS\">era</span><span class=\"iwIbEohs\">ti</span><span class=\"ZEkPBdkA\">ons</span> <span class=\"PrjNBKgh\">inv</span><span class=\"zGUlRCOf\">ol</span><span class=\"SNKXAepm\">ved</span> <span class=\"TEYrHVLp\">in</span> <span class=\"OhEbinxR\">a</span> <span class=\"YZItQZhB\">heal</span><span class=\"ZyutqKCN\">th</span> <span class=\"YAkdratS\">data</span><span class=\"jHHQHujO\">ba</span><span class=\"SuVNBZbq\">se</span> <span class=\"mhyqUmzI\">and</span> <strong><span class=\"XAQRkKwv\">bio</span><span class=\"KzGqZpju\">ban</span><span class=\"ZEkPBdkA\">ks</span></strong><span class=\"rlmifLSY\">.</span> </td>\n</tr>\n<tr>\n<td><strong><span class=\"rlmifLSY\">Oslo</span></strong></td>\n<td><span class=\"JwxnrTLx\">Sta</span><span class=\"yzPVCBHP\">teme</span><span class=\"YCqhfEbt\">nt</span> <span class=\"IIUYJKlq\">on</span> <span class=\"AakCemPk\">ther</span><span class=\"ULoaADKg\">ap</span><span class=\"tGEIBXua\">eut</span><span class=\"afenwPlA\">ic</span> <strong><span class=\"NrHhzTxg\">abo</span><span class=\"dPkdwlES\">rtio</span><span class=\"UmySEgth\">n</span></strong><span class=\"glfwYrQN\">.</span></td>\n</tr>\n<tr>\n<td><strong><span class=\"RekdhzUo\">Malt</span><span class=\"VmkSBuYK\">a</span></strong></td>\n<td><span class=\"YAkdratS\">St</span><span class=\"epNqzPAR\">at</span><span class=\"UmySEgth\">em</span><span class=\"VmkSBuYK\">en</span><span class=\"FkAqorRe\">ts</span> <span class=\"FIiuoCzU\">rela</span><span class=\"VmkSBuYK\">ted</span> <span class=\"gAQBlnIx\">to</span> <strong><span class=\"aDNXmspD\">hu</span><span class=\"tGEIBXua\">nger</span> <span class=\"ULoaADKg\">stri</span><span class=\"BWbiOGMV\">ke</span><span class=\"OiyWetMn\">s</span></strong><span class=\"rlmifLSY\">.</span></td>\n</tr>\n<tr>\n<td><strong><span class=\"UbpYdtek\">Toky</span><span class=\"UbpYdtek\">o</span></strong></td>\n<td><span class=\"ujPUriZZ\">Guid</span><span class=\"SNKXAepm\">el</span><span class=\"tGEIBXua\">in</span><span class=\"UROZKPEF\">es</span> <span class=\"wEnFNlUS\">for</span> <span class=\"FIiuoCzU\">phys</span><span class=\"glfwYrQN\">ic</span><span class=\"VXXQbRil\">ians</span> <span class=\"BWbiOGMV\">co</span><span class=\"RzCPijac\">ncer</span><span class=\"SuVNBZbq\">ning</span> <span class=\"XPoKflXW\">to</span><span class=\"wEnFNlUS\">rtur</span><span class=\"ujPUriZZ\">e</span> <span class=\"YAkdratS\">and</span> <span class=\"jONiskKP\">ot</span><span class=\"VXXQbRil\">her</span> <span class=\"epNqzPAR\">cr</span><span class=\"wEnFNlUS\">uel,</span> <span class=\"WAmDJzYv\">inhu</span><span class=\"fDcUWsKx\">man</span><span class=\"UROZKPEF\">,</span> <span class=\"KzGqZpju\">or</span> <span class=\"FkAqorRe\">degr</span><span class=\"IkuqcNUL\">adin</span><span class=\"gAQBlnIx\">g</span> <span class=\"cIAIpkTs\">trea</span><span class=\"nYUvWysW\">tmen</span><span class=\"zGUlRCOf\">t</span> <span class=\"fDcUWsKx\">or</span> <span class=\"VfIEPfbM\">puni</span><span class=\"pJPqeWdB\">sh</span><span class=\"PJsCScTL\">ment</span> <span class=\"XPoKflXW\">in</span> <span class=\"jHHQHujO\">rela</span><span class=\"gxCVxIde\">tio</span><span class=\"YZItQZhB\">n</span> <span class=\"pUJrallU\">to</span> <span class=\"pUJrallU\">deta</span><span class=\"FkAqorRe\">inme</span><span class=\"ACKoyvEy\">nt</span> <span class=\"XPoKflXW\">or</span> <strong><span class=\"rqINpOfC\">impr</span><span class=\"fDMJmOlv\">ison</span><span class=\"JwxnrTLx\">men</span><span class=\"FIiuoCzU\">t</span></strong><span class=\"XAQRkKwv\">.</span></td>\n</tr>\n<tr>\n<td><strong><span class=\"ZcoxpzJJ\">Hels</span><span class=\"PXWaTciu\">ink</span><span class=\"wEnFNlUS\">i</span></strong></td>\n<td><span class=\"MLgzMgID\">Set</span> <span class=\"RoMIvmda\">of</span> <span class=\"wdKCFutD\">et</span><span class=\"iwIbEohs\">hi</span><span class=\"jONiskKP\">cal</span> <span class=\"UROZKPEF\">prin</span><span class=\"slWdGrRE\">cipl</span><span class=\"slWdGrRE\">es</span> <span class=\"IkuqcNUL\">di</span><span class=\"UbpYdtek\">rect</span><span class=\"ZeyUVeTO\">ed</span> <span class=\"afenwPlA\">to</span> <span class=\"cIAIpkTs\">the</span> <span class=\"wEnFNlUS\">me</span><span class=\"jHHQHujO\">di</span><span class=\"YZItQZhB\">cal</span> <span class=\"JwxnrTLx\">co</span><span class=\"OMFFBaFb\">mmu</span><span class=\"gAQBlnIx\">nit</span><span class=\"pJPqeWdB\">y</span> <span class=\"RsbnHaTu\">for</span> <strong><span class=\"PDRjDLcU\">huma</span><span class=\"lnOALJQV\">n</span> <span class=\"zRDqozzn\">ex</span><span class=\"BbwPapQi\">pe</span><span class=\"BWbiOGMV\">ri</span><span class=\"RekdhzUo\">me</span><span class=\"NCJbqSkh\">nt</span><span class=\"atHJCDZp\">at</span><span class=\"wEnFNlUS\">ion</span></strong><span class=\"IkuqcNUL\">.</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM1820: Health-related International Declarations:<br><br>* Declaration of Alma-Ata (1978): Identified primary health care as the key to the attainment of the goal of Health for All.<br><br>* Ottawa Charter for Health Promotion (1986): The aim of the conference was to continue to  achieve the objectives of the World Health Organization (WHO) Health for all by the year 2000.<br><br>3. Declaration of Oslo (1970): Related to therapeutic abortion.<br><br>4. Declaration of Tokyo (1975): Guidelines for medical doctors concerning torture and other cruel, inhuman or degrading treatment or punishment in relation to detention and imprisonment. (T – Tokyo – Torture)<br><br>5. Declaration of Helsinki (1975): Related to human experimentation. (H – Helsinki – Human experimentation)<br><br>6. Declaration of Geneva (1948): Most recent amendment was done on October 14, 2017 in Chicago. It gives the modern version of the 2500-year-old Hippocratic Oath which laid down the fundamental principles of medical ethics that any physician should follow.<br><br>7. Declaration of Malta (1991, revised in 1992): Related to hunger strikes.<br><br>8. Declaration of Lisbon: Related to rights of the patients like right to information, confidentiality, dignity, freedom of choice etc.<br><br>9. Declaration of Sydney on human death: It stated that the determination of death “will be based on clinical judgment, supplemented if necessary by a number of diagnostic aids”, emphasising the EEG. Nonetheless, it asserted that “the overall judgment of the physician” could not be replaced by any ancillary test.<br><br>The statement also recommended that two or more physicians should make the diagnosis of death when organs were removed for transplantation.<br><br>10. Declaration of Istanbul: To address the urgent and growing problems of organ sales, transplant tourism and trafficking in organ donors in the context of the global shortage of organs.<br><br>11. Declaration of Taipei: Related to ethical considerations regarding health databases and biobanks.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "8. A term newborn does not cry at birth, despite stimulation. The heart rate doesn't improve even after 30 seconds of the bag and mask ventilation. Ventilation is continued and chest compressions are initiated at the lower third of the sternum. The compressions should be at the rate of",
      "choices": [
        {
          "id": 1,
          "text": "150 compressions/min"
        },
        {
          "id": 2,
          "text": "120 compressions/min"
        },
        {
          "id": 3,
          "text": "90 compressions/min"
        },
        {
          "id": 4,
          "text": "60 compressions/min"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The chest compressions should be at the rate of 90 compressions/min during neonatal resuscitation.<br><br> <br><br>The response to neonatal resuscitation at various steps is assessed based on the heart rate.<br><br>* If the heart rate is less than 100, PPV (positive pressure ventilation) is provided with bag and mask and SPO2 monitoring is done and adequate ventilation is ensured.<br><br>* If the heart rate is below 60, then chest compressions are initiated over the lower third of the sternum at a rate of 90 compressions/min.<br><br>* Recommended rate of ventilation is 30 inflations/min. (90 compressions + 30 inflation = 120 events/ min). The ratio of compressions to ventilation is 3: 1.<br><br>* If the heart rate still remains <60, despite effective compressions and ventilation, then IV epinephrine is given.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f3a7d23aa73f457fa7cc689cf7b75a61x1280x3255.JPEG\" alt=\"Explanation Image\"><br><br>Kindly note: Neonatal resuscitation is primarily to support a newborn during the transition from intrauterine to extrauterine life. AHA guidelines recommend 90 compressions/ min for neonatal resuscitation. Whereas, pediatric CPR is for cardiac arrest in infants and children. AHA guidelines recommend 100-120 compressions/ min for pediatric CPR.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "9. According to the WHO guidelines, which of the following statements are true regarding HPV vaccination?<br><br>* 3 doses schedule is recommended for young women aged 15-20 years<br><br>* 3 doses with a 6-month interval are recommended for women older than 21 years<br><br>* 3 doses (or at least 2 doses) are recommended for immunocompromised individuals<br><br>* Regardless of the duration of delay, interrupted schedules should be resumed without repeating previous doses<br><br>* All three HPV vaccines can be co-administered with other live and non-live vaccines using separate syringes and different injection sites",
      "choices": [
        {
          "id": 1,
          "text": "3, 4, 5"
        },
        {
          "id": 2,
          "text": "1, 2, 3"
        },
        {
          "id": 3,
          "text": "1, 4, 5"
        },
        {
          "id": 4,
          "text": "2, 3, 4"
        }
      ],
      "correct_choice_id": 1,
      "solution": "1 or 2 doses schedule is recommended for young women aged 15-20 years and 2 doses with a 6-month interval is recommended for women older than 21 years.<br><br>As per the December 2022 WHO Position on HPV vaccines, the recommendations for different age groups are as follows:<br><br>* 1 or 2 doses schedule for the primary target of girls aged 9-14 years.<br><br>* 1 or 2 doses schedule for young women aged 15-20 years.<br><br>* 2 doses with a 6-month interval for women older than 21 years.<br><br>* <br><br>A minimum of 2 doses and when feasible 3-doses remain necessary for those known to be immunocompromised and/or HIV-infected. <br><br>All three HPV vaccines can be co-administered with other live and non-live vaccines using separate syringes and different injection sites. Regardless of the duration of delay, interrupted schedules should be resumed as soon as possible without repeating previous doses.<br><br>WHO SAGE (Strategic Advisory Group of Experts on Immunization) recommendations regarding vaccination against HPV (Human papilloma virus) have been changed to 1 dose only. This is because a single dose has been found to provide adequate protection as comparable to 2 doses. This can help in wider coverage of vaccination of all girls in low-middle income countries.<br><br>Note: Cervavac is India's first indigenously prepared quadrivalent HPV (qHPV) vaccine.<br><br>* Targeted strains: 6, 11, 16, and 18.<br><br>* Targeted group: 9-26 years of age<br><br>* Dose and route of administration: 0.5 ml, IM.<br><br>The other available vaccinations against HPV are summarized below.<br><br><table>\n<tbody>\n<tr>\n<td><strong><span class=\"GvdyknTN\">Bran</span><span class=\"jZPxjhka\">d</span> <span class=\"BiAkqfWD\">na</span><span class=\"PVlzqXcz\">me</span></strong></td>\n<td><strong><span class=\"WHeIkXDY\">Cerv</span><span class=\"CdMIgFZi\">ari</span><span class=\"fEbETbgN\">x</span></strong></td>\n<td><strong><span class=\"eJcyrQsr\">Gard</span><span class=\"kIWvHhST\">as</span><span class=\"eddSdkXS\">il</span></strong></td>\n<td><strong><span class=\"kcnNQLCt\">Gard</span><span class=\"YmtNgEQU\">as</span><span class=\"kdpxITAY\">il</span><span class=\"CDCdemDJ\">-9</span></strong></td>\n</tr>\n<tr>\n<td><span class=\"knFqTNPG\">Char</span><span class=\"JinmTMaY\">acte</span><span class=\"oZjaDeBT\">rist</span><span class=\"CftBVwak\">ic</span> <span class=\"wPXSfVth\">and</span> <span class=\"eddSdkXS\">HPV</span> <span class=\"LXBdtlfw\">su</span><span class=\"dNcsiOaA\">bty</span><span class=\"LfyRSHbo\">pes</span></td>\n<td><span class=\"mRZazmwW\">Bi</span><span class=\"VFrNjOco\">val</span><span class=\"vMEBKHgx\">en</span><span class=\"ZWmjTqlX\">t</span> <span class=\"GvdyknTN\">:1</span><span class=\"HmfWHAJP\">6,1</span><span class=\"NEFmQvnP\">8</span></td>\n<td><span class=\"UXZzeBpP\">Qu</span><span class=\"nEXXHxXP\">adri</span><span class=\"DyYyAduN\">vale</span><span class=\"FigeNOFM\">nt:</span> <span class=\"qQjPuyZf\">6,11</span><span class=\"qQjPuyZf\">,16,</span><span class=\"MqnCXguv\">18</span></td>\n<td><span class=\"zctnHRGe\">Nona</span><span class=\"GvdyknTN\">va</span><span class=\"ifVLdkXw\">lent</span><span class=\"mMvVqKLL\">:</span> <span class=\"EGeSelSv\">6,1</span><span class=\"ccZpVClJ\">1,1</span><span class=\"adHoCPJa\">6,</span><span class=\"eVPhBpCb\">18,</span><span class=\"PVlzqXcz\">31,3</span><span class=\"kEcxomSi\">3,45</span><span class=\"yrNwfxig\">,52</span><span class=\"nEXXHxXP\">,58</span></td>\n</tr>\n<tr>\n<td><span class=\"CDCdemDJ\">Prot</span><span class=\"djytbaAl\">ect</span><span class=\"ROVIAYla\">s</span> <span class=\"cAJMHwvI\">ag</span><span class=\"zTcUcNWO\">ains</span><span class=\"MDJSgrui\">t:</span></td>\n<td><span class=\"RlJLRUCz\">CIN,</span> <span class=\"ZWmjTqlX\">Ca</span> <span class=\"zVAOSzvz\">ce</span><span class=\"ifVLdkXw\">rvix</span></td>\n<td><span class=\"GXMkVtKt\">Anog</span><span class=\"ycxksCqH\">enit</span><span class=\"ifVLdkXw\">al</span> <span class=\"kUeXScXL\">wa</span><span class=\"LXBdtlfw\">rts,</span> <span class=\"djytbaAl\">CIN</span><span class=\"zdvtmeRZ\">,</span> <span class=\"vMEBKHgx\">Ca</span> <span class=\"LXBdtlfw\">ce</span><span class=\"okEBfRaS\">rvi</span><span class=\"fEbETbgN\">x</span></td>\n<td><span class=\"SrPtQnSt\">Anog</span><span class=\"OJVYOgbk\">enit</span><span class=\"fEbETbgN\">al</span> <span class=\"zGAZfUrN\">wart</span><span class=\"dmGfXpWZ\">s,</span> <span class=\"louwubMQ\">CIN</span><span class=\"ItDjXfPk\">,</span> <span class=\"YmtNgEQU\">CA</span> <span class=\"okEBfRaS\">ce</span><span class=\"WHrJFBnq\">rvix</span><span class=\"SyPFWcsA\">,</span>  <span class=\"WlSbNdJh\">Vulv</span><span class=\"djytbaAl\">al</span> <span class=\"zGAZfUrN\">int</span><span class=\"okEBfRaS\">raep</span><span class=\"VnIRWRVo\">ithe</span><span class=\"SGQeqRNR\">lial</span> <span class=\"kcnNQLCt\">ne</span><span class=\"MMNXFFMd\">opla</span><span class=\"RlJLRUCz\">sia</span><span class=\"cRZiDGeO\">,</span> <span class=\"RlJLRUCz\">Vagi</span><span class=\"uNxjmYff\">nal</span> <span class=\"knFqTNPG\">in</span><span class=\"typwYYsw\">tr</span><span class=\"zGAZfUrN\">aepi</span><span class=\"cLghghYe\">thel</span><span class=\"DHOdwbvl\">ial</span> <span class=\"LfyRSHbo\">neop</span><span class=\"nEXXHxXP\">lasi</span><span class=\"DHOdwbvl\">a</span></td>\n</tr>\n<tr>\n<td><span class=\"JKfvzvJu\">Dos</span><span class=\"vMEBKHgx\">e</span></td>\n<td><span class=\"KnngKXiy\">0.5m</span><span class=\"IkHXeIjC\">l</span> </td>\n<td><span class=\"wPXSfVth\">0.5m</span><span class=\"uNxjmYff\">l</span></td>\n<td><span class=\"YmtNgEQU\">0.5m</span><span class=\"SrPtQnSt\">l</span></td>\n</tr>\n<tr>\n<td><span class=\"dNcsiOaA\">Adm</span><span class=\"pQsDeSjI\">in</span><span class=\"cMiGezvC\">istr</span><span class=\"wPXSfVth\">ati</span><span class=\"BiAkqfWD\">on</span></td>\n<td><span class=\"ZWmjTqlX\">0,</span> <span class=\"YNYOaksP\">1,</span> <span class=\"wPXSfVth\">6</span> <span class=\"eVPhBpCb\">mo</span><span class=\"MMNXFFMd\">nt</span><span class=\"kUeXScXL\">hs</span> <span class=\"eddSdkXS\">i.m</span></td>\n<td><span class=\"ROVIAYla\">0,</span> <span class=\"mMvVqKLL\">2,</span> <span class=\"cRZiDGeO\">6</span> <span class=\"uNxjmYff\">mont</span><span class=\"JKfvzvJu\">hs</span> <span class=\"kUeXScXL\">i.m</span></td>\n<td><span class=\"mnEMJcHS\">0,</span> <span class=\"cLghghYe\">2,</span> <span class=\"VnIRWRVo\">6mon</span><span class=\"cAJMHwvI\">th</span><span class=\"wPXSfVth\">s</span> <span class=\"cRZiDGeO\">,</span> <span class=\"kcnNQLCt\">i.m</span></td>\n</tr>\n<tr>\n<td><span class=\"zVAOSzvz\">Admi</span><span class=\"VFrNjOco\">nis</span><span class=\"EGeSelSv\">ter</span><span class=\"JKfvzvJu\">ed</span> <span class=\"gMSedsEB\">ge</span><span class=\"GvdyknTN\">nder</span></td>\n<td><span class=\"yrNwfxig\">Fem</span><span class=\"VqSqJXvr\">al</span><span class=\"fEbETbgN\">e</span> <span class=\"VblbBrLj\">and</span> <span class=\"EGeSelSv\">male</span></td>\n<td><span class=\"DHOdwbvl\">Fema</span><span class=\"UXZzeBpP\">le</span> <span class=\"qQjPuyZf\">and</span> <span class=\"GvdyknTN\">male</span></td>\n<td><span class=\"cAJMHwvI\">Fem</span><span class=\"QBdaVolg\">ale</span> <span class=\"DyYyAduN\">and</span> <span class=\"CdMIgFZi\">ma</span><span class=\"oZjaDeBT\">le</span></td>\n</tr>\n<tr>\n<td><span class=\"qQjPuyZf\">Idea</span><span class=\"vMEBKHgx\">l</span> <span class=\"dNcsiOaA\">Age</span> <span class=\"NEFmQvnP\">ran</span><span class=\"BCLfqWKQ\">ge:</span></td>\n<td><span class=\"louwubMQ\">11-1</span><span class=\"YNYOaksP\">2</span> <span class=\"HNOJlksr\">year</span><span class=\"cMiGezvC\">s,9-</span><span class=\"EGeSelSv\">26</span> <span class=\"KnngKXiy\">year</span><span class=\"OXoUxfTF\">s</span> </td>\n<td><span class=\"kUeXScXL\">11-1</span><span class=\"RlJLRUCz\">2</span> <span class=\"ipFfIsoK\">year</span><span class=\"IkHXeIjC\">s,</span> <span class=\"BCLfqWKQ\">9-26</span> <span class=\"SyPFWcsA\">year</span><span class=\"fEbETbgN\">s</span> <span class=\"GvdyknTN\">for</span> <span class=\"DHOdwbvl\">bo</span><span class=\"uNxjmYff\">th</span> <span class=\"okEBfRaS\">ma</span><span class=\"OJVYOgbk\">le</span> <span class=\"zTcUcNWO\">n</span> <span class=\"zdvtmeRZ\">fema</span><span class=\"KnngKXiy\">le</span></td>\n<td>\n<p><span class=\"MMNXFFMd\">Fe</span><span class=\"DHOdwbvl\">male</span><span class=\"eJcyrQsr\">s:11</span><span class=\"fhBgJeOw\">-12</span> <span class=\"PtnwKvNV\">year</span><span class=\"ccZpVClJ\">s,</span> <span class=\"OXoUxfTF\">9-</span><span class=\"fNkLqxRF\">26</span> <span class=\"rYCvkYon\">year</span><span class=\"dNcsiOaA\">s</span></p>\n<p><span class=\"fNkLqxRF\">Male</span><span class=\"DHOdwbvl\">s:1</span><span class=\"dNcsiOaA\">1-1</span><span class=\"gMSedsEB\">2</span> <span class=\"gFzZzHJY\">ye</span><span class=\"dNcsiOaA\">ars</span></p>\n<p><span class=\"cMiGezvC\">9-</span><span class=\"dNcsiOaA\">15</span> <span class=\"PtnwKvNV\">yea</span><span class=\"MMNXFFMd\">rs</span> <span class=\"gFzZzHJY\">-</span> <span class=\"HNOJlksr\">FDA</span> <span class=\"MfSGWyCR\">ap</span><span class=\"VFrNjOco\">pr</span><span class=\"knFqTNPG\">oved</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>January is Cervical Cancer Awareness Month, observed to raise awareness about cervical cancer and HPV vaccination. On this Cervical Cancer Awareness Month, the messages are clear.<br><br>Get informed: Find out the facts about cervical cancer & HPV that causes it. Help educate other women in your life. \nGet screened: Cervical cancer screening typically starts at age 30 and is repeated periodically. \nGet vaccinated: The HPV vaccine is given in 2 doses that should begin when a girl is between 9 and 14 years old.<br><br>With a comprehensive approach to prevent, screen and treat, we can end cervical cancer as a public health problem within a few generations.<br><br>Pearl PM2174: Human Papilloma Virus (HPV) and Associated Lesions<br><br><table>\n<tbody>\n<tr>\n<td><strong>HPV serotype</strong></td>\n<td><strong>Lesions</strong></td>\n</tr>\n<tr>\n<td>HPV 1,2,3,4</td>\n<td>\n<div class=\"page\" title=\"Page 566\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Common warts (verruca vulgaris, plantar wart)</li>\n</ul>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>HPV 6 and 11</td>\n<td>\n<ul>\n<li>Condyloma acuminatum (genital warts)</li>\n<li>Sinonasal papilloma</li>\n<li>Squamous papilloma of the larynx</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>HPV 16</td>\n<td>\n<ul>\n<li>LSIL, HSIL, carcinoma cervix</li>\n<li>Vulval carcinoma</li>\n<li>Bowen disease (Carcinoma in situ of male external genitalia)</li>\n<li>Oropharyngeal squamous cell carcinoma</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>HPV 18</td>\n<td>\n<ul>\n<li>LSIL, HSIL, Carcinoma of the cervix</li>\n<li>Carcinoma of the anogenital region</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>HPV 5 and 8</td>\n<td>\n<ul>\n<li>Squamous cell carcinoma of the skin in epidermodysplasia verruciformis patients</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br>LSIL: Low-grade squamous intraepithelial lesion<br><br>HSIL: High-grade squamous intraepithelial lesion",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "10. As per the IAP standard treatment guidelines 2022, which of the following factors are considered risk factors for developing subsequent epilepsy in a child with febrile seizures?<br><br>* Family history of epilepsy<br><br>* Any neurodevelopmental problem<br><br>* Prolonged or focal febrile seizures<br><br>* Febrile status epilepticus",
      "choices": [
        {
          "id": 1,
          "text": "Only 1 and 3"
        },
        {
          "id": 2,
          "text": "Only 2 and 4"
        },
        {
          "id": 3,
          "text": "1,2,3,4"
        },
        {
          "id": 4,
          "text": "Only 3 and 4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Risk factors for developing subsequent epilepsy in a child with febrile seizures include:<br><br>* Family history of epilepsy<br><br>* Any neurodevelopmental problem<br><br>* Prolonged or focal febrile seizures<br><br>* Febrile status epilepticus<br><br>Febrile seizures are described as seizures that occur in children of the age of 6–60 months with a temperature of 38ºC (100.4°F) or higher, without underlying intracranial infections or prior unprovoked seizures. Epilepsy is a disorder of the brain characterized by a predisposition to generate repeated seizures. Children with simple febrile seizures have a 1% risk of developing epilepsy by the age of 7 years (same as the general population) and 2.4% by 25 years of age.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "11. A 34-year-old male patient presents to the ER following a road traffic accident. His respiratory rate is 28/min and BP is 80/50 mmHg. Cyanosis and inspiratory stridor are present. He has an open fracture of the shaft of the femur. Which of the following is the most appropriate next step?",
      "choices": [
        {
          "id": 1,
          "text": "Obtain IV access to begin fluids"
        },
        {
          "id": 2,
          "text": "Reduce the shaft of the femur fracture"
        },
        {
          "id": 3,
          "text": "Endotracheal intubation and cervical spine restriction"
        },
        {
          "id": 4,
          "text": "Tube thoracostomy in the right hemithorax"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Since the given patient has signs of airway compromise such as cyanosis and tachypnea, the most appropriate next step would be endotracheal intubation and cervical spine restriction.<br><br>The primary survey consists of the following ABCDEs:<br><br>* Airway maintenance with restriction of cervical spine motion<br><br>* Breathing and ventilation<br><br>* Circulation and hemorrhage control<br><br>* Disability (assessment of neurologic status)<br><br>* Exposure and environment control<br><br>This sequence is based on the degree of threat to life that can be caused by various injuries and must always be adhered to. Therefore, the most life-threatening abnormality has to be addressed first. For example, regardless of the cause of airway compromise, the airway has to be managed on priority because a compromised airway will rapidly kill the patient. <br><br>If the patient is able to communicate verbally, the airway is unlikely to be compromised. Objective signs of airway obstruction include agitation, cyanosis, stridor, displaced trachea, and use of accessory muscles of respiration. If there is any doubt regarding the patient's ability to maintain a patent airway, a definitive airway should be established. This can be in the form of endotracheal intubation, orotracheal airway, or surgical airway (cricothyroidotomy or tracheostomy). Other indications for definitive airway include:<br><br>* Impending airway compromise — following inhalational injury, facial fractures or retropharyngeal hematoma<br><br>* Inability to maintain adequate oxygenation by facemask oxygen supplementation<br><br>* Presence of apnea<br><br>* Glasgow Coma Scale [GCS] score of 8 or less<br><br>* Prevention of aspiration of blood or vomitus<br><br>Pearl PM0343: Glasgow Coma Scale (GCS)<br><br>GCS Score<br><br>* 13-15 represent mild injury<br><br>* 9-12 represent moderate injury<br><br>* Scores ≤8 represent severe injury <br><br>Head Injury Severity: Clinical classification <br><br><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Eyes Opening</strong></p>\n</td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Spontaneously</td>\n<td>4</td>\n</tr>\n<tr>\n<td>To verbal command</td>\n<td>3</td>\n</tr>\n<tr>\n<td>To painful stimulus</td>\n<td>2</td>\n</tr>\n<tr>\n<td>Do not open</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<div class=\"page\" title=\"Page 163\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Non-testable</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>NT</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br><table>\n<tbody>\n<tr>\n<td><strong>Verbal response</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Normal-oriented conversation</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Confused</td>\n<td>4</td>\n</tr>\n<tr>\n<td>Inappropriate words only</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Sounds only</td>\n<td>2</td>\n</tr>\n<tr>\n<td>No sounds</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<div class=\"page\" title=\"Page 163\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Non-testable</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>NT</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br><table>\n<tbody>\n<tr>\n<td><strong>Motor Response</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Obeys commands</td>\n<td>6</td>\n</tr>\n<tr>\n<td>Localizes to pain</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Withdrawal response to pain</td>\n<td>4</td>\n</tr>\n<tr>\n<td>Abnormal flexion/ Decorticate posturing </td>\n<td>3</td>\n</tr>\n<tr>\n<td>Abnormal extension/ Decerebrate posturing </td>\n<td>2</td>\n</tr>\n<tr>\n<td>No motor response</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<div class=\"page\" title=\"Page 163\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Non-testable</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>NT</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Minimum value: 3<br><br>Maximum value: 15<br><br>* GCS, in particular, the motor score, is the best predictor of neurological outcome.<br><br>* If an area cannot be assessed, no numerical score is given for that region, and it is considered “non-testable.\" (NT)<br><br>* In case of endotracheal intubation or tracheostomy, the verbal component of the score is denoted as NT.<br><br>* A score of  ‘1’ is not recorded in missing components, instead, NT is used<br><br>* when a component is Not Testable, a total score is not recorded because the score will be low and this could be confusing to medical colleagues. This may also imply that the patient is more unwell than they actually are.<br><br> <br><br>NOTE: <br><br>A new parameter, \"pupil reactivity score\" has been added to GCS, and now, it is referred to as GCS-P.<br><br>P stands for \"Pupils unreactive to light\"<br><br><table>\n<tbody>\n<tr>\n<td><strong>Pupils unreactive to light</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Both pupils</td>\n<td>2</td>\n</tr>\n<tr>\n<td>One pupil</td>\n<td>1 </td>\n</tr>\n<tr>\n<td>Neither</td>\n<td> 0</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>The pupillary score is subtracted from the GCS score to give the final value. Therefore, the range of GCS-P is 1–15.<br><br>Note: The minimum frequency of observations for patients with GCS equal to 15 should be as follows, starting after the initial assessment in the emergency department:<br><br>* Half-hourly for 2 hours,<br><br>* Then 1-hourly for 4 hours,<br><br>* 2-hourly thereafter.<br><br>Should the patient with GCS equal to 15 deteriorate at any time after the initial 2-hour period, observations should revert to half-hourly and follow the original frequency schedule.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "12. A 45-year-old patient with type II diabetes mellitus has LDL cholesterol 100 mg/dL. There is no history of atherosclerotic cardiovascular disease. Which of the following is the next step in the management of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Atorvastatin"
        },
        {
          "id": 2,
          "text": "Evolocumab"
        },
        {
          "id": 3,
          "text": "No intervention required at this stage"
        },
        {
          "id": 4,
          "text": "Low-dose aspirin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "In a diabetic patient with LDL cholesterol 100 mg/dL, the next step would be to start the patient on a moderate intensity statin, in the absence of atherosclerotic cardiovascular disease (ASCVD).<br><br>The indications for starting statins as given by the American Diabetes Association (ADA) “Standards of Care in Diabetes-2024”  guidelines are as follows-<br><br>For people with diabetes and no ASCVD:<br><br>* For people with diabetes aged 20–39 years without ASCVD, initiate lifestyle therapy<br><br>* For people with diabetes aged 40–75 years without ASCVD, use moderate-intensity statin therapy in addition to lifestyle therapy<br><br>For people with diabetes and risk factors for ASCVD:<br><br>* For people with diabetes aged 20–39 years with additional ASCVD risk factors, it may be reasonable to initiate statin therapy in addition to lifestyle therapy<br><br>* For people with diabetes aged 40–75 years with one or more ASCVD risk factors, it is recommended to use high-intensity statin therapy to reduce LDL cholesterol by ≥50% of baseline and to target an LDL cholesterol goal of <70 mg/dL<br><br>* For people with diabetes aged 40–75 years at higher cardiovascular risk, especially those with multiple ASCVD risk factors and an LDL cholesterol ≥70 mg/dL (≥1.8 mmol/L), it may be reasonable to add ezetimibe or a PCSK9 inhibitor to maximum tolerated statin therapy<br><br>For people with diabetes and ASCVD:<br><br>* For people of all ages with diabetes and ASCVD, high-intensity statin therapy should be added to lifestyle therapy to reduce LDL cholesterol by ≥50% of baseline and to target an LDL cholesterol goal of <55 mg/dL<br><br>* Addition of ezetimibe or a PCSK9 inhibitor with proven benefit in this population is recommended if this goal is not achieved on maximum tolerated statin therapy<br><br>* For people with diabetes and ASCVD intolerant to statin therapy, PCSK9 inhibitor therapy with monoclonal antibody treatment, bempedoic acid therapy, PCSK9 inhibitor therapy with inclisiran siRNA should be considered as an alternative cholesterol-lowering therapy<br><br>Evolocumab (option B) is a PCSK9 inhibitor that is approved for use in patients with familial hypercholesterolemia or in patients with ASCVD who require further LDL lowering despite being on other drugs. <br><br>Low-dose aspirin (option D) is effective in reducing cardiovascular morbidity and mortality in patients who have a history of MI and stroke. However, for primary prevention (that is, without a history of any ASCVD), the benefits of aspirin have to be weighed against the potential risk of major bleeding events, especially GI bleeding. Thus, the use of aspirin for primary prevention is restricted and should only be considered in diabetic patients who have documented high cardiovascular risk, and it is generally contraindicated in patients older than 70 years of age.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "13. Sequentially arrange the following steps to be followed in breaking bad news according to the accepted standard protocol.<br><br>A. Giving knowledge and information to the patient <br><br>B. Setting up the interview<br><br>C. Addressing the patient’s emotions with empathic responses<br><br>D. Assessing the patient’s perception",
      "choices": [
        {
          "id": 1,
          "text": "A-C-B-D"
        },
        {
          "id": 2,
          "text": "B-C-A-D"
        },
        {
          "id": 3,
          "text": "B-A-C-D"
        },
        {
          "id": 4,
          "text": "B-D-A-C"
        }
      ],
      "correct_choice_id": 4,
      "solution": "According to the SPIKES protocol for breaking bad news, the correct sequence of steps to follow is given by Option 4.<br><br>* S - Setting up the interview<br><br>* P - Assessing the patient’s perception<br><br>* I - Obtaining the patient’s invitation<br><br>* K - Giving knowledge and information to the patient<br><br>* E - Addressing the patient’s emotions with empathic responses<br><br>* S - Strategy, and summary<br><br>Key components of the SPIKES strategy:<br><br>* Demonstrating empathy<br><br>* Acknowledging and validating the patient's feelings<br><br>* Exploring the patient's understanding and acceptance of the bad news<br><br>* Providing information about possible interventions",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "14. A 50-year-old postman complains of swelling of both his lower limbs. He has a feeling of heaviness in his legs and a burning sensation on the overlying skin. Physical examination reveals the findings seen in the image below. Veins in his lower limb show tortuous dilation. According to the new CEAP classification, which of the following is the correct diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Lipodermatosclerosis - C4b"
        },
        {
          "id": 2,
          "text": "Healed ulcer -C5"
        },
        {
          "id": 3,
          "text": "Atrophie blanche - C4b"
        },
        {
          "id": 4,
          "text": "Corona phlebectacia - C4c"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The given image is characteristic of atrophie blanche which is classified as C4B under CEAP guidelines.<br><br>Atrophie blanche is a localized white atrophic skin frequently surrounded by dilated capillaries and hyperpigmentation, usually seen around the ankle. This is a sign of severe chronic venous disease.<br><br>Corona phlebectatica(C4c) are fan-shaped patterns telangiectasia over ankle or foot. Considered an early sign of advanced disease.<br><br>Lipodermatosclerosis(C4b) is due to chronic inflammation and fibrosis leading to a tight, contracted, 'woody' leg. Can lead to contractures over the Achilles tendon and is a sign of severe chronic venous disease.<br><br>Healed ulcers(C5) are due to chronic venous insufficiency which leads to full-thickness loss of epithelium which may heal over time leading to scarring.<br><br>Varicose veins - are tortuous dilatation of veins due to venous insufficiency. It commonly presents as lower limb swelling with a sensation of heaviness, burning, and aching over the affected area or whole limb.<br><br>Diagnosis is majorly done using duplex ultrasound and very rarely involves MR venography or intravenous ultrasound(IVUS).<br><br>Treatment is achieved using modalities such as compression, laser ablation, endothermal ablation, radiofrequency ablation, endovenous glue, ultrasound-guided foam sclerotherapy, open surgery, etc.<br><br>Pearl PM2292: CEAP Classification of Chronic Lower Extremity Venous Disease<br><br><table><colgroup><col/><col/><col/> </colgroup>\n<tbody>\n<tr>\n<td colspan=\"3\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 995\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>CEAP (Clinical-Etiology-Anatomy-Pathophysiology)</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Clinical classification (C)*</strong></p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C0</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>No visible or palpable signs of venous disease</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C1</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Telangiectases or reticular veins</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C2</p>\n<p>C2r</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Varicose veins</p>\n<p>Recurrent varicose veins</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C3</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Edema</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C4</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Changes in skin and subcutaneous tissue secondary</p>\n<p>to chronic venous disease</p>\n<p>C4a-Pigmentation or eczema</p>\n</div>\n</div>\n</div>\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C4b-Lipodermatosclerosis or atrophie blanche</p>\n<p>C4c-Corona phlebectatica</p>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C5</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Healed ulcer</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C6</p>\n<p>C6r</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Active ulcer</p>\n<p>Recurrent active venous ulcer</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>S</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>With symptoms attributable to venous disease</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Absence of symptoms attributable to venous disease</p>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Etiological</strong> <strong>classification (E)</strong></p>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ec</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Congenital (Klippel-Trenaunay syndrome)</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ep</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Primary</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Es</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Secondary (postthrombotic syndrome, trauma)</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Esi</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Secondary (intravenous)</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ese</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Secondary (extravenous)</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ec</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Congenital</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>En</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>No venous cause identified</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Anatomic</strong> <strong>classification</strong> <strong>(A)</strong></p>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>As</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Superficial</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ad</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Deep</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ap</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Perforator</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>An</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>No venous location identified</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Patho-physiologic classification (P)</strong></p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Pr</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Reflux</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Po</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Obstruction, thrombosis</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Pr,o</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Reflux and obstruction</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Pn</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>No venous pathophysiology identified</p>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Note:<br><br>* The descriptor A (asymptomatic) or S (symptomatic) is placed after the C clinical class.<br><br>* Telengiactesia refers to tiny intradermal venules <1 mm in diameter.<br><br>* Reticular veins refer to small dilated subdermal blue veins of 1 to 2.9 mm<br><br>* Varicose veins refer to dilated tortuous veins >3 mm in diameter",
      "explanation_video": "",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/098d18b9d0d34b6f842258b4a46adf7d.JPEG"
      ],
      "explanation_images": []
    },
    {
      "text": "15. As per the MoHFW guidelines for use of paracetamol following vaccinations, all of the following are correct, except that ______.",
      "choices": [
        {
          "id": 1,
          "text": "Number of paracetamol syrup bottles available for a session should be 10% more than the total number of doses of pentavalent and DPT expected to be administered in the session."
        },
        {
          "id": 2,
          "text": "Paracetamol syrup should be regularly administered to all children following DPT/ Pentavalent vaccination to prevent onset of fever."
        },
        {
          "id": 3,
          "text": "One bottle of syrup paracetamol  should be dispensed only to children who have been administered pentavalent or DPT in the vaccination session."
        },
        {
          "id": 4,
          "text": "If paracetamol suspension is supplied in place of syrup, the bottle should be shaken for 10 seconds before use and this should be demonstrated to the parent."
        }
      ],
      "correct_choice_id": 2,
      "solution": "Paracetamol syrup should not be regularly administered to all children following DPT/ Pentavalent vaccination. Paracetamol syrup should be administered only if there is fever following vaccination (axillary temperature>38oC/ 100.4oF or child feels hot to touch).<br><br>The Ministry of Health and Family Welfare (MoHFW) guidelines for use of paracetamol following vaccinations recommend the following:<br><br>* The number of paracetamol syrup bottles available for a session should be 10% more than the total number of doses of pentavalent and DPT expected to be administered in the session.<br><br>* One bottle of syrup paracetamol should be dispensed only to children who have been administered pentavalent or DPT in the vaccination session.<br><br>* If paracetamol suspension is supplied in place of syrup, the bottle should be shaken for 10 seconds before use and this should be demonstrated to the parent.<br><br>* Paracetamol syrup should be administered only if there is fever following vaccination (axillary temperature>38oC/ 100.4oF or child feels hot to touch). The age-wise dose of paracetamol syrup (125 mg/ 5 mL) in infants is: (@10–15 mg/kg body weight)<br><br>* 6 weeks - 6 months - 2.5 mL<br><br>* 6 - 24 months - 5 mL<br><br>* 2 - 4 Years - 7.5 mL<br><br>* 4 - 6 years - 10 mL <br><br>* Paracetamol is not recommended in children weighing <2 kg<br><br>* Maximum of four doses in 24 hours, with a gap of at least four hours between two doses",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "16. A 60-year-old female has been admitted for a thorough evaluation following a history of right-sided weakness that resolved by the time she reached the hospital 2 hours after the onset. MRI of the brain reveals no signal changes. During rounds the next morning, the resident is asked about the patient's ABCD2 score. What does this score measure?",
      "choices": [
        {
          "id": 1,
          "text": "Risk of future stroke"
        },
        {
          "id": 2,
          "text": "Need for anticoagulation"
        },
        {
          "id": 3,
          "text": "Risk of pulmonary embolism"
        },
        {
          "id": 4,
          "text": "Severity of sub-arachnoid hemorrhage"
        }
      ],
      "correct_choice_id": 1,
      "solution": "Transient ischemic attack (TIA) is defined as an episode of stroke symptoms that last <24 hours, which is the likely diagnosis according to the clinical scenario. The ABCD2 Score is used to measure the risk of stroke in a patient following TIA.<br><br>TIAs occur due to an embolic clot to the brain or a thrombosis within an intra-cranial vessel similar to what happens in an ischemic stroke, but in TIA, the vessel lumen opens up spontaneously leading to resolution of the neurologic symptoms. The risk of developing a stroke following a TIA is high especially during the first few hours-days, and hence patients are usually admitted to the hospital and started on dual anticoagulation with aspirin + clopidogrel, which has been found to prevent stroke following TIA. Thrombolysis is not indicated in TIA but is indicated in early stroke occurring following TIA.<br><br>Other options:<br><br>Option B: The CHA2DS2 VASc Score is to assess the risk for embolic stroke in patients with atrial fibrillation. Based on the risk determined, the need for anticoagulation is decided.<br><br>Option C: The risk for developing pulmonary embolism is based on the Well’s, Modified Well’s and Pulmonary Embolism Rule-out Criteria (PERC) scoring systems.<br><br>Option D: The severity of sub-arachnoid hemorrhage according on the clinical status of the patient at the time of presentation is based on the Hunt and Hess Score. It is used to predict the clinical outcome of the patient, ie, higher score indicates poorer outcome.<br><br>Pearl PM1813: ABCD2 Score<br><br>The risk of stroke following TIAs is determined by ABCD2 score:<br><br><table>\n<tbody>\n<tr>\n<td><strong>Risk factors</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td><strong>A</strong>ge <span>&gt;</span> 60 </td>\n<td>1</td>\n</tr>\n<tr>\n<td>S<strong>B</strong>P&gt;140 mmHg or D<strong>B</strong>P &gt;90 mmHg</td>\n<td>1</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>C</strong>linical symptoms:</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Unilateral weakness</li>\n</ul>\n</td>\n<td>2</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Speech disturbances without weakness</li>\n</ul>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>D</strong>uration:</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>&gt;60 minutes</li>\n</ul>\n</td>\n<td>2</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>10 - 59 minutes</li>\n</ul>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td><strong>D</strong>iabetes</td>\n<td>1</td>\n</tr>\n<tr>\n<td><strong>Total score</strong></td>\n<td><strong>Sum each score</strong></td>\n</tr>\n<tr>\n<td>ABCD2 Score Total</td>\n<td>3-months Rate of stroke (%)</td>\n</tr>\n<tr>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td>1</td>\n<td>2</td>\n</tr>\n<tr>\n<td>2</td>\n<td>3</td>\n</tr>\n<tr>\n<td>3</td>\n<td>3</td>\n</tr>\n<tr>\n<td>4</td>\n<td>8</td>\n</tr>\n<tr>\n<td>5</td>\n<td>12</td>\n</tr>\n<tr>\n<td>6</td>\n<td>17</td>\n</tr>\n<tr>\n<td>7</td>\n<td>22</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM1200: CHA2DS2-VASC scoring for risk of stroke & need for oral anticoagulation in AF<br><br><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Components</strong></p>\n</td>\n<td>\n<p><strong>Points</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>C – Congestive heart failure</p>\n</td>\n<td>\n<p>1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>H - Hypertension</p>\n</td>\n<td>\n<p>1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>A – Age &gt; 75 years</p>\n</td>\n<td>\n<p>2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>D – Diabetes Mellitus</p>\n</td>\n<td>\n<p>1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>S – Stroke/TIA/TE</p>\n</td>\n<td>\n<p>2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p class=\"p1\">VASc-Vascular disease (prior MI, Peripheral Arterial Disease,</p>\n<p class=\"p1\">or aortic plaque)</p>\n</td>\n<td> 1</td>\n</tr>\n<tr>\n<td> A- Age 65–74 years</td>\n<td> 1</td>\n</tr>\n<tr>\n<td> S- sex category (i.e., female sex)</td>\n<td> 1</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br><table>\n<tbody>\n<tr>\n<td>\n<p><strong>CHADS2 score</strong></p>\n</td>\n<td>\n<p><strong>Antithrombotics </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>0</p>\n</td>\n<td>\n<p>Aspirin or no antithrombotics</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>Aspirin or oral anticoagulant</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;1</p>\n</td>\n<td>\n<p>Oral anticoagulant</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM2392: Clinical prediction for pulmonary embolism: Well’s, Modified Well’s and Pulmonary Embolism Rule out Criteria (PERC)<br><br><table>\n<tbody>\n<tr>\n<td><strong>Signs/symptoms</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Clinical signs of DVT</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Diagnosis other than pulmonary embolism is less likely</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Heart rate &gt;100 bpm</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>Immobilization for &gt;3 days or surgery in the last 4 weeks</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>Past history of DVT/pulmonary embolism</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>Hemoptysis</td>\n<td>1</td>\n</tr>\n<tr>\n<td>Malignancy</td>\n<td>1</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Three-level score probability:<br><br><table>\n<tbody>\n<tr>\n<td><strong>Well's criteria</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Low</td>\n<td>&lt;2</td>\n</tr>\n<tr>\n<td>Moderate</td>\n<td>2-6</td>\n</tr>\n<tr>\n<td>High</td>\n<td>&gt;6</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Two-level score probability:<br><br><table>\n<tbody>\n<tr>\n<td><strong>Modified Well's criteria</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Pulmonary embolism unlikely</td>\n<td>≤4</td>\n</tr>\n<tr>\n<td>Pulmonary embolism likely</td>\n<td>&gt;4 </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br>Pulmonary embolism rule out criteria (PERC):<br><br>This is a quick OPD/casualty tool to rule out pulmonary embolism in patients with low clinical probability. It comprises eight clinical variables. If the patient meets all eight criteria, there is no need for further investigations. The variables include: <br><br>* Age <50 years<br><br>* Heart rate <100 bpm<br><br>* SpO2 ≥95%<br><br>* No unilateral leg swelling<br><br>* No hemoptysis<br><br>* No recent trauma or surgery<br><br>* No history of venous thromboembolism<br><br>* No use of hormonal therapy.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "17. The cut-off value for treatment in neonatal hypogylcemia is ________",
      "choices": [
        {
          "id": 1,
          "text": "Blood glucose < 40 mg/dL"
        },
        {
          "id": 2,
          "text": "Blood glucose < 50 mg/dL"
        },
        {
          "id": 3,
          "text": "Blood glucose < 60 mg/dL"
        },
        {
          "id": 4,
          "text": "Blood glucose < 70 mg/dL"
        }
      ],
      "correct_choice_id": 1,
      "solution": "The cut-off for the treatment of neonatal hypoglycemia is a Blood glucose level of <40 mg/dL .<br><br>This is particularly applicable after the initial 2–3 hours of life. Babies showing blood glucose <40 mg/dL on a reagent strip should be treated for hypoglycemia. Since reagent strips have high false-positive rates, a confirmation of hypoglycemia by a lab test is recommended.<br><br>Neonatal hypoglycemia can be suspected when blood glucose level is <45 mg/dL.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "18. An international traveler wants to get vaccinated against typhoid. Which of the following is true when concerning the safety of the Ty21a vaccine?",
      "choices": [
        {
          "id": 1,
          "text": "It can be given simultaneously with other live vaccines"
        },
        {
          "id": 2,
          "text": "It can be given to patients taking anti-bacterial drugs"
        },
        {
          "id": 3,
          "text": "It is efficacious in patients having acute diarrhoea"
        },
        {
          "id": 4,
          "text": "It can be given safely to HIV patients with CD4 <200 as long as they are asymptomatic"
        }
      ],
      "correct_choice_id": 1,
      "solution": "Other live vaccines can be given simultaneously with the Ty21a typhoid vaccine. <br><br>Ty21a is a live-attenuated oral vaccine for individuals ≥5 years of age.<br><br>* The regimen is 1st, 3rd, and 5th day - 3 doses.<br><br>* Repeat every 3 years for endemic areas, and every year for traveling individuals. <br><br>Not recommended in:<br><br>* Patients on antimitotic drugs and immunosuppressants<br><br>* Acute febrile illness<br><br>* Acute intestinal infestation<br><br>* Congenital or acquired immunodeficiency<br><br>Ty21a vaccine can be administered in an HIV-positive asymptomatic patient as long as the CD4+ count is >200/ cubic mm. <br><br>Proguanil and antibacterial drugs should be stopped from 3 days before to 3 days after the vaccine. <br><br>The vaccine is unlikely to be effective if it is administered at the time of ongoing diarrhea.<br><br>Other available vaccines against typhoid include:<br><br>* Inactivated whole cell vaccine<br><br>* Injectable Vi polysaccharide vaccine<br><br>* Vi-rEPA vaccine<br><br>Pearl PM0689: Types of Vaccines<br><br><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type</strong></p>\n</td>\n<td>\n<p><strong>Vaccines</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Live attenuated</p>\n</td>\n<td>\n<p>Mumps</p>\n<p>BCG</p>\n<p>Influenza (cold-adapted)</p>\n<p>Typhoid (oral)</p>\n<p>YelloW fever</p>\n<p>Rubella and Rotavirus</p>\n<p>Oral Polio (Sabin)</p>\n<p>Measles</p>\n<p>Japanese Encephalitis</p>\n<p>Varicella</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Killed whole organism</p>\n</td>\n<td>\n<p>Rabies</p>\n<p>Influenza</p>\n<p>Polio (IPV, Salk)</p>\n<p>Hep A</p>\n<p>Cholera</p>\n<p>Encephalitis</p>\n<p>Plague</p>\n<p>Typhoid</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Toxoid/Protein</p>\n</td>\n<td>\n<p>Diphtheria</p>\n<p>Tetanus</p>\n<p>Acellular Pertussis</p>\n<p>Anthrax</p>\n<p>Influenza subunit </p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Polysaccharide</p>\n</td>\n<td>\n<p>Pneumococcus</p>\n<p>Meningococcus</p>\n<p>Hemophilus influenza type b (Hib)</p>\n<p>Typhoid (Vi) </p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glycoconjugate</p>\n</td>\n<td>\n<p>Hib</p>\n<p>Pneumococcus</p>\n<p>MenACWY(meningococcal vaccine) </p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Recombinant</p>\n</td>\n<td>\n<p>Hepatitis B vaccine</p>\n<p>Lyme disease</p>\n<p>Cholera toxin B</p>\n<p>HPV </p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "19. The correct sequence for phlebotomy according to the WHO guidelines is:",
      "choices": [
        {
          "id": 1,
          "text": "A, B, E, D, and C"
        },
        {
          "id": 2,
          "text": "B, A, E, D, and C"
        },
        {
          "id": 3,
          "text": "A, B, C, E, and D"
        },
        {
          "id": 4,
          "text": "C, B, A, E, and D"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The correct sequence for phlebotomy (withdrawal of blood) according to the WHO guidelines is:  <br><br>B – Assembling of equipment<br><br>A – Performing Hand hygiene<br><br>E – Wearing gloves<br><br>D – Withdrawing blood<br><br>C – Labelling of tubes & checking accuracy  <br><br>The WHO has laid down guidelines for the best practices in Phlebotomy. The following illustrations depict the same:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/536eacf30f984e5687dd1dbfaebe549cx449x743.JPEG\" alt=\"Explanation Image\"><br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3c70567d643a4429aba6df061a0bc804x395x1062.JPEG\" alt=\"Explanation Image\"><br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3e35dcf1d8dc43f196d5a6cb6e6e8ba5x410x856.JPEG\" alt=\"Explanation Image\"><br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4448d667c33e4363ad66c07a57a0085cx368x620.JPEG\" alt=\"Explanation Image\"><br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a155bafb064742ae8d46d83978754acbx314x483.JPEG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/61819fc6eb0f4ae7bfb6fb83ec967eb7.JPEG"
      ],
      "explanation_images": []
    },
    {
      "text": "20. Where are blood bags and urine bags discarded, according to biomedical waste management?",
      "choices": [
        {
          "id": 1,
          "text": "Both are disposed of in yellow container"
        },
        {
          "id": 2,
          "text": "Both are disposed of in red container"
        },
        {
          "id": 3,
          "text": "Urine bag in red container and blood bag in yellow container"
        },
        {
          "id": 4,
          "text": "Urine bag in yellow container and blood bag in red container"
        }
      ],
      "correct_choice_id": 3,
      "solution": "According to biomedical waste management, the urine bags are supposed to be disposed of in the red container and blood bags in the yellow container.<br><br>Pearl PM0038: Biomedical waste disposal<br><br> <br><br><table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><span><strong> <span> Yellow bag </span></strong><strong><span>(non-chlorinated)</span></strong><strong><span> </span> </strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Type of Waste</p>\n</td>\n<td> Treatment and Disposal Options</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human anatomical waste</strong></p>\n<p><strong>Animal anatomical waste</strong></p>\n</td>\n<td>\n<p><strong>Incineration</strong>/Plasma pyrolysis/Deep Burial</p>\n</td>\n</tr>\n<tr>\n<td><strong>Soiled Waste: </strong>Items like dressings, cotton swabs, and plaster casts contaminated with blood and body fluids and bags containing residual discarded blood.</td>\n<td>\n<p><strong>Incineration</strong>/Plasma pyrolysis/Deep Burial</p>\n<p>or</p>\n<p>Autoclaving/Microwaving/ Hydroclaving</p>\n<p>Later - Shredding/mutilation</p>\n</td>\n</tr>\n<tr>\n<td>Discarded linen, mattresses, beddings contaminated with blood or body fluid,<strong> routine masks, and gowns</strong></td>\n<td>\n<p>Non- chlorinated chemical disinfection<br/>followed by incineration or Plazma<br/>Pyrolysis or for energy recovery.<br/>In absence of the above facilities, shredding, mutilation, or a combination of sterilization and shredding is used.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Microbiology, biotechnology, clinical laboratory waste</strong></p>\n<p>(Autoclave safe plastic bags used)</p>\n<p><strong>Blood bags</strong>, laboratory<br/>cultures, stocks or specimens of microorganisms,<br/>live or attenuated vaccines, human and animal cell cultures used in research, industrial laboratories, production of biological, residual toxins, dishes, and devices used for cultures.</p>\n</td>\n<td>\n<p>Pre-treatment with nonchlorinated chemicals</p>\n<p>Later - Incineration</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Expired/discarded medicine, cytotoxic drugs</p>\n</td>\n<td>Incineration/plasma pyrolysis/ disposal in a secured landfill</td>\n</tr>\n<tr>\n<td> \n<p><strong>Chemical waste</strong></p>\n<p>Chemicals used in biological production and used or discarded<br/>disinfectants.</p>\n</td>\n<td>\n<p>Disposal- incineration/plasma<br/>pyrolysis</p>\n<p>Encapsulation- hazardous waste treatment, storage, and disposal facility.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Chemical liquid</strong> <strong>waste</strong> :<br/>Liquid waste generated due to the use of chemicals in the production of<br/>biological and used or <strong>discarded disinfectants,</strong> silver X-ray film<br/>developing liquid,<br/>discarded formalin,<br/>infected <strong>secretions,</strong><br/><strong>aspirated body fluids</strong>, liquid from laboratories and floor washings, cleaning, house-keeping and<br/>disinfecting activities etc.</p>\n<p> </p>\n</td>\n<td>After resource recovery, the chemical<br/>liquid waste shall be pre-treated before mixing with other wastewater. </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br><table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><span><strong>  Red bag (non-chlorinated)  </strong></span></p>\n</td>\n</tr>\n<tr>\n<td><strong> Type of Waste</strong></td>\n<td>\n<p><strong> <span>Treatment and Disposal Options</span></strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Recyclable contaminated</strong> waste</p>\n<p>Contaminated waste tubing, bottles, intravenous tubes and sets, <strong>catheters,</strong> <strong>urine bags</strong>, syringes (without needles and fixed needle syringes with their needles cut), <strong>vacutainers with</strong> <strong>needles cut,</strong> and gloves.</p>\n</td>\n<td>\n<p><strong>Autoclaving/Microwaving/<br/>Hydroclaving</strong></p>\n<p>Followed by Shredding/mutilation</p>\n<p>And later, Energy recovery/Plastics to diesel or fuel oil/road-making</p>\n<p>Not to be sent to landfill</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br><table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><strong>  White (translucent)  <br/>(puncture-proof, leak-proof containers)</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Type of Waste</strong></td>\n<td>\n<p><strong>Treatment and Disposal Options</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Waste Sharps including metals.</strong></p>\n<p>Needles, syringes with fixed needles, needles from needle tip cutter or burner, scalpels, blades, or any other <strong>contaminated sharp</strong> object that may cause puncture and cuts. This includes both used, discarded, and contaminated metal sharps</p>\n</td>\n<td>\n<p>Autoclaving/ Dry heat sterilization</p>\n<p>Followed by - <strong>Shredding/mutilation</strong>/<br/>encapsulation</p>\n<p>Later by - Iron foundries/sanitary landfill/waste sharps</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br><table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p> <span><strong><span>  Blue  </span><br/></strong></span><span><strong><span>(Puncture proof and leak proof containers with blue colored marking)</span></strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type of Waste </strong></p>\n</td>\n<td>\n<p><strong> Treatment and Disposal Options</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Glassware</strong></p>\n<p>Broken or discarded and contaminated glass including medicine <strong>vials</strong> and <strong>ampules except</strong> those containing <strong>cytotoxic</strong> waste.</p>\n<p><strong>Metallic body implants</strong></p>\n</td>\n<td>\n<p>Sodium hypochlorite/Autoclaving/<br/>Microwaving/Hydroclaving</p>\n<p>Later - Recycling</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br> Note: Ash from the incineration of biomedical waste shall be disposed of at a common hazardous waste treatment and disposal facility. However, it may also be disposed of in a municipal landfill, if the toxic metals in incineration ash are within the regulatory quantities as defined under the Hazardous Waste (Management and Handling and Transboundary Movement) Rules, 2008 as amended from time to time.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}